News
Stay up to date on the latest company news:
4 November 2025
Abalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025
23 October 2025
Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors
14 October 2025
Abalos Therapeutics Publishes in Cell Reports Medicine Validating ABX-001's Potential to Overcome Cancer Immunotherapy Hurdles
09 October 2024
Abalos Therapeutics Appoints Gerben Moolhuizen as Chief Executive Officer
18 March 2024
Abalos selected for funding project by KMU-innovativ, an initiative from Germany‘s Federal Ministry of Education and Research (BMBF)
18 October 2022
Abalos Therapeutics Appoints Thomas Bogenrieder as Chief Medical Officer
12 August 2022
Abalos Therapeutics---arenaviruses take on cancer
14 October 2021
Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million
05 February 2020
Abalos Therapeutics Expands Leadership Team with Drug Development and Viral Therapy Manufacturing Experts
15 October 2019
Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer
Events
Want to get in touch with the Abalos Therapeutics Team? Meet us at the following events:
October 17-21, 2025
ESMO Congress 2025
Location: Berlin, Germany
Participant: Gerben Moolhuizen, CEO / Thomas Bogenrieder, CMO
November 3-5, 2025
Bio-Europe 2025
November 5-9, 2025
SITC 2025
Location: Washington D.C., USA
Participants: Gerben Moolhuizen, CEO /
Karl Lang, Chair of Immunology at the Medical Faculty, University Duisburg-Essen
November 17-20, 2025
Jefferies Global Healthcare Conference
December 1-3, 2025
Cell & Gene Therapy International Europe 2025
December 10-12, 2025
ESMO Immuno-Oncology Congress 2025
Location: London, UK
Participant: Karl Lang, Chair of Immunology at the Medical Faculty, University Duisburg-Essen